RAYMOND JAMES[®] **CHRIS RAPER** & ASSOCIATES

Chris's Timely Market Dispatch

November 10th, 2020

As you are now no doubt aware, Pfizer's promising <u>COVID-19 vaccine news</u> on Monday, November 9th, 2020 lit a fire under global capital markets, with COVID victim type stocks rallying strongly on this potential game changing event. As I write, the markets / investors (which are forward looking animals) are voting overwhelmingly in favour of this being a major win against the COVID-19 battle. Here are some highlights from the Pfizer press release:

- 43,538 participants, which includes the placebo and the trial vaccine
- No side effects reported
- 90% efficacy seven days after the second dose

"Today is a great day for science and humanity" – Dr. Albert Bourla, Pfizer Chair & CEO.

When I heard the news, my first thought was of my much beloved parents who live in the Atlantic bubble. I have been unable to see them since the lockdown began. Dare I hope to visit them by summer? All of the sudden, it seems possible.

How does that translate to the matter at hand, i.e. protecting and growing your money? For us, it is important to understand what is going on sector by sector and stock by stock, as opposed to the headlines – essentially, what is going on "under the hood". By way of example, the S&P 500 index (\$SPX) closed up a modest +1.17% on Monday, last. No big deal, right? Well not so fast... as you can see from the table below, previous COVID beneficiaries rolled south in big way, whereas COVID victims blew the doors off.

Select COVID Beneficiaries / Victims Monday, November 9th, 2020 One Day Performance

Beneficiaries	% Change	Victims	% Change
DocuSign	-13.60%	Lamb Weston*	14.28%
Shopify	-12.06%	TJX Companies*	12.90%
Etsy	-17.15%	Mastercard*	9.86%
Williams-Sonoma*	-9.99%	Suncor Energy	24.67%
Netflix	-7.30%	Gibson Energy*	8.67%

*Holdings within The Dividend Value Discipline™

Yes, it is only one day and there are a lot of hurdles to overcome – production, distribution and efficacy on the most vulnerable are all potential vaccine potholes in the road to normalcy. In the interim, we have to deal with the exponential growth in cases and hospitalizations that we are witnessing on our daily news feeds.

Turning to the U.S. presidential race, the rally post-election is the historical norm, regardless of which party / presidential candidate prevails. Investors mistakenly tend to wait for the outcome before committing their capital. Counterintuitively, if there are far fewer buyers in the lead up to the election, what happens to price? To wit, to the Friday, October 30th close, the S&P 500 was down -5.6% on the week. Watching it unfold and knowing the CNN Fear & Greed Index hit a low of 25 (Extreme Fear) earlier that week, we did work up the courage to invest

some of our modest cash resources on the Friday before the election. True to form, the markets rallied strongly the day of the election but well before the outcome was known. With the Biden presidency all but certain and the upper house (Senate) looking like the Republicans will prevail, investors started to see the outcome as best of both worlds. There will be less breaking of the china in the White House (pun intended ©), and Biden will be unable to make much progress on raising taxes. To the Friday, November 6th close, the S&P 500 rallied +7.2% on the week, once again underlying the importance of being a student of history.

At times like this, it is important to keep one's exuberance in check – we are inclined towards incrementalism as opposed to wholesale change. There will be potholes in the road to post-pandemic recovery. For now, please be assured that we continue to see the future from a glass half full perspective, and are acutely aware of what is happening "under the hood" and will adjust accordingly as the evidence evolves.

Have a great week,

Yours truly,

Chris Raper

Senior Vice-President | Senior Wealth Advisor

Chris Raper & Associates - the most proactive wealth advisory team on planet Earth

CHRIS RAPER & ASSOCIATES **RAYMOND JAMES**

Information in this article is from sources believed to be reliable; however, we cannot represent that it is accurate or complete. It is provided as a general source of information and should not be considered personal investment advice or solicitation to buy or sell securities. The views are those of the author, Chris Raper and Ryan Cramp, and not necessarily those of Raymond James Ltd. Investors considering any investment should consult with their Investment Advisor to ensure that it is suitable for the investor's circumstances and risk tolerance before making any investment decision. Raymond James Ltd. is a Member Canadian Investor Protection Fund. This provides links to other Internet sites for the convenience of users. Raymond James Ltd. is not responsible for the availability or content of these external sites, nor does Raymond James Ltd endorse, warrant or guarantee the products, services or information described or offered at these other Internet sites. Users cannot assume that the external sites will abide by the same Privacy Policy which Raymond James Ltd adheres to. Raymond James (USA) Ltd. is a member of FINRA/SIPC